Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

HistoIndex's AI-based Digital Pathology Platform: A Validated Quantification Tool Recommended in the Guidelines for the Prevention and Treatment of Chronic Hepatitis B in China


News provided by

HistoIndex

24 May, 2020, 22:00 GMT

Share this article

Share toX

Share this article

Share toX

SINGAPORE, May 24, 2020 /PRNewswire/ -- Singapore medtech company HistoIndex's AI-based stain-free digital pathology platform has long been established as a suitable tool for global clinical guidelines that outline the assessment, prevention and treatment of Chronic Hepatitis B (CHB) infections. In the latest edition of China's Guidelines for the Prevention and Treatment of Chronic Hepatitis B [1], the digital pathology platform was recommended for use in providing an automated and quantitative analysis of the liver's morphological characteristics in unstained liver biopsies with high repeatability and accuracy.

Continue Reading
This image opens in the lightbox
Figure 1: Stain-free images from HistoIndex’s AI-based digital pathology platform show a reduction of fibrous septa (in green) after treatment. After the images are produced, the platform generates data on the assessment of fibrosis parameters, which are crucial in determining treatment evaluation and modification.

Challenges in Treating CHB Patients

Hepatitis B has been known as a complex disease to treat, due to the challenge in distinguishing patients with an active infection. These patients require intervention as opposed to patients with an inactive infection who require only standard monitoring without treatment. For patients with an active CHB infection, the treatment decision is usually based on the increased level of alanine aminotransferase (ALT) indicating an inflammation of the liver, high HBV-DNA serum level and the presence of the Hepatitis B e-antigen. However, these levels do not determine the presence and level of fibrosis in the liver.

To prevent the progression of CHB to cirrhosis or Hepatocellular Carcinoma (HCC), it is important to identify patients whose livers are affected by advanced fibrosis prior to therapy, as the post treatment prognosis depends on the stage of fibrosis. This can only be achieved with a fibrosis assessment by performing a liver biopsy, the current gold standard in evaluating the degree of inflammation, necrosis, and fibrosis in all liver conditions.

Identifying Significant Morphological Features

Besides evaluating the severity of fibrosis and inflammation in biopsies via conventional observations, it is important to accurately assess dynamic changes in the extracellular matrix of the liver, especially the various degrees of fibrous enlargement in the liver. Having a very precise measurement of these features will help clinicians to understand the stage of fibrosis in a patient and carry out a suitable treatment management plan for their patients. Enabled by Second Harmonic Generation (SHG), HistoIndex's AI-based platform has been noted in multiple publications and studies for its ability to accurately and automatically quantify changes in liver fibrosis that are both observable and subtle, and critical for treatment evaluation and modification.

In a study in 2018, fibrosis changes were evaluated with the SHG platform CHB patients before and after 78 weeks' antiviral therapy, with results encouraging the use of this tool to assess the efficacy of new anti-fibrotic therapies in clinical trials [2]. An interesting observation from this study was the reduction in fibrous septa after treatment, which showed treatment efficacy and was analyzed with precision by the SHG platform (Figure 1). Therefore, this platform will be beneficial as an assistive tool for CHB-related diagnosis, as well as for monitoring the efficacy of antiviral therapies during CHB clinical trials. This is synonymous with the SHG platform's recommendation by China's guidelines for its value in providing an automated and quantitative analysis for the assessment of CHB.

Image Credits: Quantitative assessment of liver fibrosis (qFibrosis) reveals precise outcomes in Ishak "stable" patients on anti-HBV therapy, Scientific Reports [2]. This image is an excerpt of the original, which can be found in the cited publication. All images and third-party materials in this publication are included in its Creative Commons license, CC BY 4.0.

Says Professor You Hong*, Chief Physician and Professor at the Beijing Friendship Hospital (affiliated with the Capital Medical University) and a co-author of the 2018 study, "As a clinician, we need to make practical and reasonable decisions for our patients. Including intelligent and reliable clinical tools such as the SHG platform in the guidelines will greatly enhance our diagnostic capability and personalize our treatment options in managing patients with CHB. Having utilized this platform in our studies has helped us to observe significant changes in the vital fibrosis parameters that are crucial in determining the severity of CHB and deciding the appropriate treatment route." Professor You is a Key Opinion Leader (KOL) in the Hepatology field, and her additional appointments include Deputy Director of the Chinese Society of Hepatology and Steering Committee Member of APASL.

Dr Dean Tai, Chief Scientific Officer of HistoIndex, adds, "We have substantial data from studies conducted with the involvement of KOLs that show the potential of our AI-based platform, in the area of CHB as well as Nonalcoholic Steatohepatitis (NASH). I am confident that our platform will contribute significantly if implemented in similar international clinical guidelines, as well as in consortiums and workgroups that have been set up globally for the management of CHB."

China: Bearing a Heavy Disease Burden

As one of the countries battling CHB infections, China has the highest burden in the world, with one third of the world's infected people living in China [3]. Most of them are unaware of their infection, making this disease a truly silent epidemic. With limited access to diagnosis and treatment, these people face a bleak future as their condition will eventually progress – without treatment – to cirrhosis and eventually, liver cancer. About 10 million people living with CHB will die by 2030 [4] [5], with most of these deaths being avoidable. As part of efforts to help the nation in this devastating disease, experts under the Chinese Medical Association's (CMA) Infectious Diseases and Liver Diseases Branch released the updated guidelines in 2019.

EDITOR'S NOTES

* Professor You Hong is also the Assistant Dean at the Capital Medical University, where she holds additional appointments as Director of the Office of Academic Research and Director of the Experimental Center.

A Major and Growing Global Health Concern

According to the World Health Organization (WHO), CHB has resulted in an estimated 887,000 deaths in 2015, mostly from cirrhosis and hepatocellular carcinoma (i.e. primary liver cancer), and 257 million people are living with CHB as of the same year. As of 2016, 27 million people were aware of their infection, while only 4.5 million of the people diagnosed were on treatment [6]. Following WHO's call to eliminate viral hepatitis as a public health problem, and bring down new infections by 90% and reduce deaths by 65% by 2030, countries across the world have implemented clinical guidelines to standardize and aid in the prevention, diagnosis and antiviral therapy of CHB:

(a)  According to the American Association for the Study of Liver Diseases (AASLD) practice guidance, a liver biopsy should be considered in patients with persistently borderline normal or slightly elevated ALT levels, particularly those who have been infected with HBV for a long period of time and are now older than 40 years of age [7]. 

(b) Similarly, in the European Association for the Study of the Liver (EASL) 2017 Clinical Practice Guidelines on the management of Hepatitis B Virus Infections, patients without cirrhosis should be considered for treatment when their severity of liver disease assessed traditionally by liver biopsy shows at least moderate necroinflammation and/or at least moderate fibrosis [8].

(c)  In the 2016 update of the Asian-Pacific Association for the Study of the Liver (APASL) Consensus Guidelines on Invasive and Non-invasive Assessment of Hepatic Fibrosis, the liver biopsy remains the gold standard for assessing liver fibrosis. Interestingly, the guidelines acknowledged a possible shift from routine light microscopy to digital image analysis, and the incorporation of numerical measurements in conjunction with the integrated analysis of other cellular information [9]. Since then, microscopy and analysis of liver fibrosis has indeed been transformed; pathologists today are assisted by smart digital pathology tools to make accurate and objective assessments of fibrosis and other relevant features in the liver.

References

1.  Chinese Medical Association Infectious Diseases Branch, Chinese Medical Association Hepatology Branch. Guidelines for the Prevention and Treatment of Chronic Hepatitis B (2019 Edition) [J]. Chinese Journal of Clinical Infectious Diseases, 2019, 12 (6): 401-428.: 10.3760 / cma.j.issn.1674-2397.2019.06.001.

Note: The Chinese Journal of Clinical Infectious Diseases website is in Mandarin and is enabled with an automatic prompt that offers the option for an English translation.

2.  Sun, Y., Zhou, J., Wu, X. et al. Quantitative assessment of liver fibrosis (qFibrosis) reveals precise outcomes in Ishak "stable" patients on anti-HBV therapy. Sci Rep 8, 2989 (2018). https://doi.org/10.1038/s41598-018-21179-2

3.  Shanquan Chen, Jun Li, Dan Wang, Hong Fung, Lai-yi Wong, Lu Zhao. The Hepatitis B epidemic in China should receive more attention. The Lancet Volume 391, Issue 10130, P1572, April 21, 2018. https://doi.org/10.1016/S0140-6736(18)30499-9.

4.  World Health Organization. Global Hepatitis Report 2017. Accessed 29 April 2020.

5.  World Health Organization. Up to 10 million people in China could die from chronic hepatitis by 2030 – Urgent action needed to bring an end to the 'silent epidemic'. Accessed 29 April 2020.

6.  World Health Organization, Hepatitis B Fact Sheet. Accessed 29 April 2020.

7.  Terrault, N.A., Lok, A.S., McMahon, B.J., Chang, K.‐M., Hwang, J.P., Jonas, M.M., Brown, R.S., Jr., Bzowej, N.H. and Wong, J.B. (2018), Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance. Hepatology, 67: 1560-1599. doi:10.1002/hep.29800.

8.  European Association for the Study of the Liver, EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. Volume 67, Issue 2, P370-398, August 01, 2017. https://doi.org/10.1016/j.jhep.2017.03.021

9.  Sarin, S.K., Kumar, M., Lau, G.K. et al. Asian-Pacific Clinical Practice Guidelines on the Management of Hepatitis B: A 2015 Update. Hepatol Int 10, 1–98 (2016). https://doi.org/10.1007/s12072-015-9675-4

Media Contacts: Ms Cynthia Anne Victor, Corporate Communications & PR, HistoIndex, cynthia.victor@histoindex.com

Photo - https://mma.prnewswire.com/media/1171910/Fibrous_Septa_Quantitative_assessment_of_liver_fibrosis_HistoIndex_Credits1.jpg

Related Links

https://www.histoindex.com/

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.